Indivior Pharmaceuticals, Inc.
INDV
$34.62
-$0.15-0.43%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.58% | 19.17% | 19.73% | 2.28% | 1.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.58% | 19.17% | 19.73% | 2.28% | 1.00% |
| Cost of Revenue | -7.69% | -9.09% | 14.29% | -17.86% | -34.18% |
| Gross Profit | 18.00% | 24.77% | 20.80% | 6.77% | 13.64% |
| SG&A Expenses | -22.78% | -8.27% | -11.43% | 0.00% | 3.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 66.67% | -125.00% | -- |
| Total Operating Expenses | -21.21% | -14.07% | -8.54% | -7.91% | -10.12% |
| Operating Income | 126.76% | 117.91% | 150.94% | 26.09% | 69.05% |
| Income Before Tax | 158.06% | 98.28% | 113.16% | 23.33% | 151.67% |
| Income Tax Expenses | -13.64% | 136.36% | -223.53% | -162.50% | 291.30% |
| Earnings from Continuing Operations | 577.78% | 89.36% | 385.71% | 90.91% | 118.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 577.78% | 89.36% | 385.71% | 90.91% | 118.56% |
| EBIT | 126.76% | 117.91% | 150.94% | 26.09% | 69.05% |
| EBITDA | 123.29% | 111.43% | 145.45% | 23.96% | 65.91% |
| EPS Basic | 611.94% | 89.37% | 394.27% | 101.56% | 120.04% |
| Normalized Basic EPS | 174.45% | 144.85% | 200.90% | 33.84% | 67.39% |
| EPS Diluted | 600.00% | 82.06% | 376.07% | 106.25% | 119.44% |
| Normalized Diluted EPS | 165.53% | 137.24% | 193.17% | 30.69% | 66.04% |
| Average Basic Shares Outstanding | -4.80% | 0.00% | -1.75% | -5.30% | -7.41% |
| Average Diluted Shares Outstanding | -1.59% | 3.20% | 0.81% | -3.01% | -6.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |